Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents
Norberto Perico, Monica Cortinovis, Fredy Suter, et al.
The Lancet Infectious Diseases (2022) Vol. 23, Iss. 1, pp. e22-e33
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 375
Could the fibromyalgia syndrome be triggered or enhanced by COVID-19?
Maria Fernanda Pessano Fialho, Evelyne da Silva Brum, Sara Marchesan Oliveira
Inflammopharmacology (2023) Vol. 31, Iss. 2, pp. 633-651
Open Access | Times Cited: 25
A retrospective cohort study on early antibiotic use in vaccinated and unvaccinated COVID‐19 patients
Carlo Brogna, Luigi Montano, Maria Elisabetta Zanolin, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 3
Open Access | Times Cited: 9
Meta-Analysis of Glucocorticoids for Covid-19 Patients Not Receiving Oxygen
Remo Daniel Covello, Laura Pasin, Stefano Fresilli, et al.
NEJM Evidence (2023) Vol. 2, Iss. 5
Open Access | Times Cited: 18
Ibuprofen, other NSAIDs and COVID-19: a narrative review
William Laughey, Imran Lodhi, Graham Pennick, et al.
Inflammopharmacology (2023) Vol. 31, Iss. 5, pp. 2147-2159
Open Access | Times Cited: 16
Phytochemical analysis, GC–MS profile and determination of antibacterial, antifungal, anti-inflammatory, antioxidant activities of peel and seeds extracts (chloroform and ethyl acetate) of Tamarindus indica L
Adinath N. Tavanappanavar, Sikandar I. Mulla, Chandra Shekhar Seth, et al.
Saudi Journal of Biological Sciences (2023) Vol. 31, Iss. 1, pp. 103878-103878
Open Access | Times Cited: 16
The effect of microbiome therapy on COVID-19-induced gut dysbiosis: A narrative and systematic review
Mahmoud Yousef, Mlaak Rob, Sanish Varghese, et al.
Life Sciences (2024) Vol. 342, pp. 122535-122535
Open Access | Times Cited: 6
Immune cell-derived extracellular vesicles for precision therapy of inflammatory-related diseases
Shuo Li, Wenqing Li, Xianggui Wu, et al.
Journal of Controlled Release (2024) Vol. 368, pp. 533-547
Closed Access | Times Cited: 5
A SARS-CoV-2 mucosal nanovaccine based on assembly of maltodextrin, STING agonist and polyethyleneimine
Yu Tian, Liang Hu, Qingrui Huang, et al.
International Journal of Biological Macromolecules (2025), pp. 139395-139395
Closed Access
What have we learnt from the COVID-19 pandemic?
Shampa Chatterjee, Amaro Nunes Duarte‐Neto, Marco Cascella, et al.
Elsevier eBooks (2025), pp. 867-892
Closed Access
Production of medical knowledge between resilience and sharing: the case of a community of practice at the time of COVID-19
Fabio Lucchini
International Review of Sociology (2025), pp. 1-16
Closed Access
The translational potential of studying bat immunity
Kaushal Baid, Aaron T. Irving, Nolwenn Jouvenet, et al.
Trends in Immunology (2024) Vol. 45, Iss. 3, pp. 188-197
Closed Access | Times Cited: 4
Anti-inflammatory effects of quercetin, rutin, and troxerutin result from the inhibition of NO production and the reduction of COX-2 levels in RAW 264.7 cells treated with LPS
Gi Baek Lee, Yohan Kim, Kyung Eun Lee, et al.
Research Square (Research Square) (2024)
Closed Access | Times Cited: 4
Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases, in Patients with Cardiac Issues, and in the Healthy Population
Loredana Frasca, Giuseppe Ocone, Raffaella Palazzo
Pathogens (2023) Vol. 12, Iss. 2, pp. 233-233
Open Access | Times Cited: 10
Repurposing of halogenated organic pollutants via alkyl bromide-catalysed transfer chlorination
Heng Liu, Ding‐Wei Ji, Yong‐Kang Mei, et al.
Nature Chemistry (2024) Vol. 16, Iss. 9, pp. 1505-1514
Closed Access | Times Cited: 3
Modulation of innate immunity related genes resulting in prophylactic antimicrobial and antiviral properties
Veronica Ferrucci, Marco Miceli, Chiara Pagliuca, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Anti-Inflammatory Effects of Quercetin, Rutin, and Troxerutin Result From the Inhibition of NO Production and the Reduction of COX-2 Levels in RAW 264.7 Cells Treated with LPS
Gi Baek Lee, Yohan Kim, Kyung Eun Lee, et al.
Applied Biochemistry and Biotechnology (2024)
Closed Access | Times Cited: 3
Mucosal SARS-CoV-2 Nanoparticle Vaccine Based on Mucosal Adjuvants and Its Immune Effectiveness by Intranasal Administration
Lucheng Xiao, Weili Yu, Lijuan Shen, et al.
ACS Applied Materials & Interfaces (2023) Vol. 15, Iss. 30, pp. 35895-35905
Closed Access | Times Cited: 9
Design, Synthesis, Drug-Likeness, anti-Inflammatory, Antimicrobial Activity, and Molecular Docking Studies of Pyrimidine Analogs
N. Jeelan Basha, K. T. Akshay
Polycyclic aromatic compounds (2024), pp. 1-13
Closed Access | Times Cited: 2
Diclofenac, ibuprofen, and paracetamol biodegradation: overconsumed non-steroidal anti-inflammatories drugs at COVID-19 pandemic
Beatriz L. Ferreira, Dionisia P. Ferreira, Swanny F. Borges, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 6
Blood-brain barrier breakdown in COVID-19 ICU survivors: an MRI pilot study
Wen Shi, Dengrong Jiang, Hannah Rando, et al.
NeuroImmune Pharmacology and Therapeutics (2023) Vol. 2, Iss. 4, pp. 333-338
Open Access | Times Cited: 6
On the Use of Orthoformates as an Efficient Approach to Enhance the Enzymatic Enantioselective Synthesis of (S)-Ibuprofen
Oussama Khiari, Nassima Bouzemi, J.M. Sánchez-Montero, et al.
Catalysts (2023) Vol. 13, Iss. 2, pp. 251-251
Open Access | Times Cited: 5
Deciphering the potential therapeutic targets and mechanisms of jaranol for the treatment of COVID-19 and lung adenocarcinoma
Zhongcui Kang, Qian Wu, Qihang Peng, et al.
Arabian Journal of Chemistry (2024) Vol. 17, Iss. 3, pp. 105648-105648
Open Access | Times Cited: 1
COVID-19 monitoring of school personnel through molecular salivary test and dried blood spot analysis
Dolaji Henin, Clara Fappani, Daniela Carmagnola, et al.
Journal of Global Health (2024) Vol. 14
Open Access | Times Cited: 1
The potential for OGG1 inhibition to be a therapeutic strategy for pulmonary diseases
Lang Pan, István Boldogh
Expert Opinion on Therapeutic Targets (2024) Vol. 28, Iss. 3, pp. 117-130
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top